Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Thromboembolism Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Thromboembolism Overview | 9 | 1 |
| Pipeline Products for Thromboembolism Comparative Analysis | 10 | 1 |
| Thromboembolism Therapeutics under Development by Companies | 11 | 1 |
| Thromboembolism Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Thromboembolism Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Thromboembolism Products under Development by Companies | 16 | 1 |
| Thromboembolism Products under Investigation by Universities/Institutes | 17 | 1 |
| Thromboembolism Companies Involved in Therapeutics Development | 18 | 11 |
| Bayer AG | 18 | 1 |
| Cereno Scientific AB | 19 | 1 |
| China Biologic Products, Inc. | 20 | 1 |
| Daiichi Sankyo Company, Limited | 21 | 1 |
| F. Hoffmann-La Roche Ltd. | 22 | 1 |
| Gamma Therapeutics, Inc. | 23 | 1 |
| GlycoMimetics, Inc. | 24 | 1 |
| Green Cross Corporation | 25 | 1 |
| Ionis Pharmaceuticals, Inc. | 26 | 1 |
| Portola Pharmaceuticals, Inc. | 27 | 1 |
| The International Biotechnology Center (IBC) Generium | 28 | 1 |
| Thromboembolism Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 42 |
| alteplase biosimilar Drug Profile | 38 | 1 |
| antithrombin III (human) Drug Profile | 39 | 1 |
| betrixaban Drug Profile | 40 | 4 |
| C-3 Drug Profile | 44 | 1 |
| CS-1 Drug Profile | 45 | 1 |
| edoxaban tosylate Drug Profile | 46 | 5 |
| Gammarin Drug Profile | 51 | 1 |
| GCC-2107 Drug Profile | 52 | 1 |
| GMI-1271 Drug Profile | 53 | 5 |
| IONIS-FXIRx Drug Profile | 58 | 3 |
| Lysimab Drug Profile | 61 | 1 |
| Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism Drug Profile | 62 | 1 |
| Recombinant Protein for Thromboembolism Drug Profile | 63 | 1 |
| rivaroxaban Drug Profile | 64 | 13 |
| TAP-ANV Drug Profile | 77 | 1 |
| TRX-1 Drug Profile | 78 | 1 |
| YG-001 Drug Profile | 79 | 1 |
| Thromboembolism Dormant Projects | 80 | 1 |
| Thromboembolism Discontinued Products | 81 | 1 |
| Thromboembolism Product Development Milestones | 82 | 18 |
| Featured News &Press Releases | 82 | 1 |
| May 27, 2016: Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting | 82 | 1 |
| May 23, 2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on Betrixaban at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting | 83 | 1 |
| Apr 06, 2016: Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis SSC Meeting 2016 on May 27, 2016 | 83 | 1 |
| Mar 30, 2016: Bristol-Myers Squibb And Pfizer Announce Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology S 65Th Annual Scientific Session | 84 | 4 |
| Mar 24, 2016: Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients | 88 | 1 |
| Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer | 89 | 2 |
| Nov 30, 2015: New Data from Bayer s Portfolio in Thrombosis to be Presented at ASH 2015 | 91 | 1 |
| Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015 | 91 | 3 |
| Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients | 94 | 1 |
| Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis | 95 | 1 |
| Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients | 96 | 1 |
| Sep 24, 2015: Bayer s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis | 96 | 1 |
| Sep 24, 2015: Bayer s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis | 97 | 1 |
| Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots | 97 | 1 |
| Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer | 98 | 2 |
| Appendix | 100 | 2 |
| Methodology | 100 | 1 |
| Coverage | 100 | 1 |
| Secondary Research | 100 | 1 |
| Primary Research | 100 | 1 |
| Expert Panel Validation | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |